Surgical pathology clinicsHumansBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleReceptors
Hormone Receptor and HER2 Testing in Breast Cancer: Latest Questions Answered.
Joanna Solarewicz, Kimberly H Allison
Published: 202510.1016/j.path.2025.07.004
Abstract
Evolving data continue to require pathologists to adjust breast cancer biomarker interpretation and reporting. ER low positive and HER2 low/ultralow are not distinct subtypes of breast cancer but have important treatment implications. ER low positive…
Preview only. Read the full abstract at the source